PCSK9 inhibition with a novel fusion protein Oral PCSK9 inhibition: Clinical update VICTORION-INITIATE supports early inclisiran treatment in ASCVD LIBerate-HR: Lerodalcibep reduces LDL-C in high and very high risk CVD US patients missing out on bempedoic acid Evolocumab benefits in patients with autoimmune and inflammatory diseases

Marianna Pavlyha Articles

Apo(a) size and PAD revascularisation outcomes: What’s the link?

High Lp(a) increases the risk of peripheral arterial disease (PAD) and adverse limb events,1 and apo(a) is an essential component of Lp(a). Apo(a) is expressed as large and small isoforms, and small size is associated with higher Lp(a) levels and greater risk of cardiovascular disease.2,3…

Posted on 6 December 2023 | Posted by Marianna Pavlyha | Posted in Expert views, Videos

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters